BioLineRx Names Philip A. Serlin as Chief Executive Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Roth Capital Keeps VBL Therapeutics (VBLT) at 'Buy' Following Q2 Results; Glioblastoma Remains in Focus
August 15, 2016 12:20 PM EDTRoth Capital affirms VBL Therapeutics (Nasdaq: VBLT) at Buy with a price target of $17 following Q2 results reported earlier Monday.
Analyst Joseph Pantginis commented today, In June, VBLT updated clinical results from a Phase I/II trial of VB-111 in the treatment of patients with recurrent platinum resistant ovarian cancer. The results showed a median overall... More
Roth Remains Positive on BioLineRx (BLRX) Following Q2 Report, CEO Succession
August 11, 2016 11:46 AM EDTRoth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $7 following Q2 results and appointment of a new CEO, as announced early Thursday.
Analyst Joseph Pantginis commented, The company has several important catalysts slated by year-end, which should be able to address the recent... More
BioLineRx (BLRX) Misses Q2 EPS by 2c; Updates on Remaining FY16 Milestones
August 11, 2016 7:19 AM EDTBioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07).
Expected upcoming significant milestones for remainder of 2016:
Initiation of Phase 2a study in pancreatic cancer, under immuno-oncology collaboration with Merck, following expected regulatory approval in Q3... More